{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/prescribing-information/oral-fluconazole/","result":{"pageContext":{"chapter":{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole","depth":2,"htmlHeader":"<!-- begin field 98bbc592-a637-43d2-8e1a-23da9198c150 --><h2>Oral fluconazole</h2><!-- end field 98bbc592-a637-43d2-8e1a-23da9198c150 -->","summary":"","htmlStringContent":"<!-- begin item c6c542ca-1285-49a5-ad2f-3700e6f0b6b5 --><!-- end item c6c542ca-1285-49a5-ad2f-3700e6f0b6b5 -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"48a88474-766a-5209-ab6f-bea6539297ae","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 2e67c569-0e77-4231-a23d-a6b400d99442 --><h3>What are the contraindications and cautions for oral fluconazole?</h3><!-- end field 2e67c569-0e77-4231-a23d-a6b400d99442 -->","summary":"","htmlStringContent":"<!-- begin item 4e14c4f3-a3d1-4031-bcf1-a6b400d991ef --><!-- begin field a42025b3-c242-4dd0-abbe-a6b400d99442 --><ul><li><strong>Do not prescribe:</strong><ul><li><strong>Oral fluconazole to:</strong><ul><li>Women with acute porphyria.</li><li>Pregnant women.</li><li>Women taking <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-fluconazole/#drug-interactions\">certain drugs</a>.</li></ul></li><li><strong>High or repeated doses of oral fluconazole to:</strong><ul><li>Breastfeeding women.</li></ul></li></ul></li><li><strong>Prescribe oral fluconazole with caution to women:</strong><ul><li>At risk of QT interval prolongation — this includes women with cardiomyopathy, sinus bradycardia, arrhythmias, hypokalaemia, hypomagnesaemia, hypocalcaemia, and those taking other drugs known to cause QT interval prolongation (such as tricyclic antidepressants, antipsychotics, or antiarrhythmics).</li><li>With hepatic impairment or taking concurrent hepatotoxic drugs, due to the risk of hepatic necrosis — discontinue if signs or symptoms of hepatic disease develop (such as severe abdominal pain, jaundice, or weakness).  </li><li>With renal impairment (estimated glomerular filtration rate [eGFR] less than 50mL/min/1.73m<sup>2</sup>) — use the usual initial dose then halve any subsequent doses.</li><li>Who are taking <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-fluconazole/#drug-interactions\">certain drugs</a>.</li></ul></li><li><strong>Oral fluconazole can be purchased over-the-counter for the self-treatment of recurrent vulvovaginal candidiasis. However:</strong><ul><li>It should not be used long term without medical advice, <em>and</em></li><li>Assessment by a healthcare professional is indicated in certain cases, for example in girls younger than 16 years, women older than 60 years, or if the person develops systemic symptoms. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/recurrent-infection/#general-advice-on-self-management\">Self-management advice</a> for more information.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]</p><!-- end field a42025b3-c242-4dd0-abbe-a6b400d99442 --><!-- end item 4e14c4f3-a3d1-4031-bcf1-a6b400d991ef -->","subChapters":[]},{"id":"cc2e5dea-8108-58a7-8a80-4d40a44eff13","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 05ad613c-a0cf-4650-9769-a6b400da4c4c --><h3>What adverse effects are associated with oral fluconazole?</h3><!-- end field 05ad613c-a0cf-4650-9769-a6b400da4c4c -->","summary":"","htmlStringContent":"<!-- begin item 50d6ad8a-33a7-43a1-a6b4-a6b400da4ae3 --><!-- begin field b61d2963-354f-4ba7-ad97-a6b400da4c4c --><ul><li><strong>Adverse effects of oral fluconazole include:</strong><ul><li><strong>Common or very common</strong><ul><li>Abdominal discomfort, diarrhoea, nausea, and flatulence.</li><li>Headache.</li><li>Rash — discontinue treatment if the infection becomes invasive or systemic.</li></ul></li><li><strong>Uncommon</strong><ul><li>Alopecia.</li><li>Adrenal insufficiency.</li><li>Dizziness.</li><li>Vomiting, dyspepsia, and taste disturbance.</li><li>Hepatic disorders.</li><li>Hyperlipidaemia.</li><li>Seizures.</li><li>Pruritus, anaphylaxis, angioedema (in children), hypersensitivity reactions (in adults), Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul></li><li><strong>Frequency unknown</strong><ul><li>Hypokalaemia.</li><li>Leucopenia and thrombocytopenia.</li></ul></li></ul></li><li>Severe cutaneous reactions are more likely in people with AIDS.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]</p><!-- end field b61d2963-354f-4ba7-ad97-a6b400da4c4c --><!-- end item 50d6ad8a-33a7-43a1-a6b4-a6b400da4ae3 -->","subChapters":[]},{"id":"8a27c0f2-efa6-5d15-8847-d7a7af37e143","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7e51e473-d0ec-457d-9191-a6b400daaf45 --><h3>What drug interactions are associated with oral fluconazole?</h3><!-- end field 7e51e473-d0ec-457d-9191-a6b400daaf45 -->","summary":"","htmlStringContent":"<!-- begin item 26ec9cc3-77bb-42a1-a239-a6b400daad8b --><!-- begin field 4f8291ce-611e-44c7-9ec9-a6b400daaf45 --><ul><li><strong>Fluconazole inhibits the metabolism of drugs metabolized by the cytochrome P450 enzymes CYP2C9 (potently), CYP3A4 (moderately), and CYP2C19</strong><strong>. This may result in a higher and/or prolonged action of these drugs, including adverse effects. </strong>The enzyme-inhibiting effect of fluconazole persists 4–5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole. In general, fluconazole interactions relate to multiple-dose treatments.<ul><li><strong>The following drugs are contraindicated (or should be avoided) during treatment with fluconazole:</strong><ul><li>Ergotamine — there is an increased risk of ergotism.</li><li>Erythromycin — concurrent use with fluconazole has the potential to increase the risk of cardiotoxicity (prolonged QT interval and Torsades de Pointes) and consequently sudden heart death.</li><li>Pimozide — concurrent use with fluconazole may lead to QT prolongation and rare occurrences of Torsade de Pointes.</li><li>Quetiapine.</li><li>Reboxetine.</li></ul></li><li><strong>Concurrent treatment with f</strong><strong>luconazole and the following drugs </strong><strong>should be done with caution </strong>(concurrent use should be monitored; dose adjustments may be indicated):<ul><li>Aminophylline and theophylline.</li><li>Avanafil.</li><li>Ciclosporin.</li><li>Coumarins, such as warfarin. </li><li>Diazepam (risk of prolonged sedation).</li><li>Fentanyl.</li><li>Midazolam (risk of prolonged sedation).</li><li>Phenytoin.</li><li>Rifabutin (increased risk of uveitis).</li><li>Statins — the risk of myopathy and rhabdomyolysis increases when fluconazole is given with statins metabolized through CYP3A4 (atorvastatin and simvastatin) or through CYP2C9 (fluvastatin). If concurrent treatment is necessary, monitor for symptoms of myopathy and rhabdomyolysis, and monitor creatine kinase. Discontinue the statin if a marked increase in creatine kinase is observed or if myopathy/rhabdomyolysis is diagnosed or suspected.</li><li>Sulfonylureas (such as gliclazide and glipizide) — if concurrent use is indicated, advise the person to seek medical advice if they have symptoms of hypoglycaemia (for example nervousness, sweating, and/or trembling).</li><li>Tacrolimus and sirolimus.</li><li>Tretinoin — fluconazole possibly increases the risk of tretinoin toxicity.</li><li>Zidovudine — fluconazole increases the risk of zidovudine toxicity. </li></ul></li></ul></li><li><strong>Other possible drug interactions of fluconazole include:</strong><ul><li>Clopidogrel — fluconazole possibly reduces the antiplatelet effect of clopidogrel.</li><li>Hydrochlorothiazide — the plasma levels of fluconazole may be increased by 40%; however, no adjustment in dosage of fluconazole is required. </li><li>Rifampicin — metabolism of fluconazole may be accelerated by rifampicin, leading to reduced plasma concentrations.</li></ul></li><li><strong>For a complete list of possible drug interactions of fluconazole, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]</p><!-- end field 4f8291ce-611e-44c7-9ec9-a6b400daaf45 --><!-- end item 26ec9cc3-77bb-42a1-a239-a6b400daad8b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}